VBI Vaccines (VBIV) Granted FDA Approval of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/22/2022
- Wall Street ends mixed after punishing week
- Broadcom (AVGO) in Talks to Acquire VMware (VMW) - WSJ
- '3600 is the New Bull Case': Outflows from Energy and Materials Highest in Several Years - BofA
- Dollar catches a break after bruising week as investors turn risk averse
- Apple (AAPL) is a 'Compelling Name To Own' Right Now, iPhone Sales Trending Ahead of Guidance - Wedbush's Ives
- UPDATE: BofA Securities Initiates Novavax (NVAX) at Underperform
- Covetrus (CVET) Receives $21 Per Share Offer from Clayton, Dubilier & Rice and TPG
- Upstart Holdings (UPST) Sinks as Wedbush Cuts Target After Analyzing Pending Securitization
- '3600 is the New Bull Case': Outflows from Energy and Materials Highest in Several Years - BofA
- UPDATE: German Court Bans Ford (F) From Producing, Selling Cars: Wiwo - Bloomberg
- Pre-Open Stock Movers 05/20: Deckers, Palo Alto Jump on Results; Ross Stores Sinks (more...)
- Companies with NDRs 5/20
- After-Hours Stock Movers 05/19: Palo Alto Ramps on Strong Results; Ross Stores Plunges (more...)
- Companies with NDRs 5/19
- After-Hours Stock Movers 05/18: Cisco Plunges on Weak Results and Outlook; Synopsys Jumps on Results (more...)
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
August 30, 2017 8:00 AM EDTCAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 08/30/17 --
-- Sci-B-Vac is a third-generation hepatitis B vaccine, approved for use in Israel and 14 other countries -- VBI expects to initiate enrollment in a Phase 3 clinical program later in the second half of 2017 in the U.S., Europe and CanadaVBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for a Phase 3 clinical program evaluating Sci-B-Vac, VBI's third-generation hepatitis B... More
